Search - Prime Therapeutics
Navigate to
-
Eyebrow High-Cost Therapy Profile: February Detailed information about Marnetegragene autotemcel Intravenous (IV) High Cost Therapy Profile Gene Therapy/Immunology Marnetegragene autotemcel...
-
publications Optimizing immunoglobulin use in multiple myeloma: clinical and managed care perspectives September 19, 2025 Author: Abby Kim, PharmD, BCOP Multiple myeloma (MM) is a hematologic...
-
Prime works to simplify medication management and support patients with migraine, making migraine treatment less of a pain point
Prime Article: Stories -
Managed Markets Insight & Technology (MMIT)
PA Sub-Categories: Specialty drugs Products Prime Article: In the News -
publications BiTEs and roadblocks June 25, 2025 Author: Simone Ndujiuba, PharmD, BCOP US Food and Drug Administration (FDA) has approved fourteen bispecific antibody drugs to treat a variety of...
-
Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s
PA Sub-Categories: GLP-1 Prime Article: Perspectives -
Breadcrumb Home Newsroom Custom Content Prime Careers Spotlight Prime Careers Spotlight: September 2025 Prime Careers Spotlight: September 2025 Check out our latest job openings. Together, we can...
-
publications Innovations Driving the Future of Breast Cancer Care October 21, 2025 Author: Abby Kim, PharmD, BCOP October marks Breast Cancer Awareness Month - a time to spotlight innovations...
-
Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.
PA Sub-Categories: GLP-1 Specialty drugs Products Prime Article: Press Releases -
Read Clinical News: August 2024 Your monthly source for drug information highlights Clinical News Your monthly source for drug information highlights Hot topics FDA SAFETY ALERT ON COMPOUNDED...
-
publications GLP-1 Pipeline Update: November 2024 Quarterly view of the GLP-1 pipeline and anticipated indications November 21, 2024 Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Vice...
-
Publications Clinical Highlights: March 2025 Your monthly source for drug information highlights. March 27, 2025 Trending topics As of late February 2025, the United States (U.S.) Centers for...
-
publications Trending Topics & Drug Approvals: August 2025 Your source for the latest drug information highlights August 29, 2025 Trending Topics Hot topics BARDA research update The United...
-
publications Quarterly Drug Pipeline: October 2024 Clinical insights and competitive intelligence on anticipated drugs in development October 31, 2024 Editor-in-chief's message Welcome to the Prime...
-
publications Quarterly Drug Pipeline: July 2024 Clinical insights and competitive intelligence on anticipated drugs in development Editor-in-chief's message Welcome to the Prime Quarterly Drug...
-
publications Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development July 31, 2025 Editor-in-chief's message Welcome to Prime...
-
Quarterly Drug Pipeline: April 2024 Clinical insights and competitive intelligence on anticipated drugs in development Drug Pipeline Clinical insights and competitive intelligence on anticipated...
-
publications Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development April 25, 2025 Editor-in-chief's message Welcome to the Prime...
-
publications Quarterly Drug Pipeline: October 2025 Clinical insights and competitive intelligence on anticipated drugs in development October 30, 2025 Editor-in-chief's message Welcome to the Prime...
-
Quarterly Drug Pipeline: January 2024 Clinical insights and competitive intelligence on anticipated drugs in development Drug Pipeline Clinical insights and competitive intelligence on anticipated...
-
publications Quarterly Drug Pipeline: January 2025 Clinical insights and competitive intelligence on anticipated drugs in development January 30, 2025 Editor-in-chief's message Welcome to the Prime...